Nisan 2021
Inflamatuvar bagirsak hastaliginda nonalkolik yagli karaciger hastaligi sikligi
Prevalence of nonalcoholic fatty liver disease in inflammatory bowel disease
- Ana Sayfa
- Sayılar
- Nisan 2021
- Inflamatuvar bagirsak hastaliginda nonalkolik yagli karaciger hastaligi sikligi...
Erzurum Egitim ve Arastirma Hastanesi, 2Gastroenteroloji Bölümü, Erzurum
Özet
Giris ve Amaç: Nonalkolik yagli karaciger hastaligi, inflamatuvar bagirsak hastaliginda yaygindir. Bu çalismanin amaci inflamatuvar bagirsak hastaliginda nonalkolik yagli karaciger hastaligi prevalansini eslestirilmis bir kontrol grubuyla karsilastirildiginda degerlendirmek ve inflamatuvar bagirsak hastaliginda nonalkolik yagli karaciger hastaligi ile iliskili özellikleri tanimlamaktir. Gereç ve Yöntem: Karin agrisi nedeniyle gastroenteroloji poliklinik kontrollerinde ultrasonografi tetkiki yapilan 225 inflamatuvar bagirsak hastaligi tanili olgunun tibbi kayitlari geriye dönük olarak incelendi. Bu olgular yas ve vücut kitle indeksi ile Diabetes Mellitus varligi açisindan eslestirilmis, inflamatuvar bagirsak hastaligi olmayan 70 kontrol olgusu ile karsilastirildi. Batin ultrasonografi verileri, karacigerdeki hepatosteatoz varligi veya yoklugu açisindan analiz edildi. Bulgular: Çalisma popülasyonu içinde nonalkolik yagli karaciger hastaligi orani %38.3 saptandi. Inflamatuvar bagirsak hastalarinda kontrolgrubuna göre anlamli olarak daha yüksek oranda nonalkolik yagli karaciger hastaligi izlendi (%43.3’e karsi %25; p = 0.004). Ülseratif kolit alt grubunda kontrol grubuna göre anlamli olarak daha yüksek oranda nonalkolik yagli karaciger hastaligi izlendi (%43.9’a karsi %25, p = 0.007). Crohn hastaligi alt grubunda kontrol grubuna göre anlamli olarak daha yüksek oranda yagli karaciger izlendi (%42.4’e karsi %25, p = 0.015). Inflamatuvar bagirsak hastaligi varliginin, Diabetes Mellitus varliginin, vücut kitle indeksinin >25 üzerinde olmasinin bagimsiz olarak nonalkolik yagli karaciger hastaligi gelisimi riskini arttirdigi saptandi. Sonuç: Inflamatuavar bagirsak hastaligi varligi nonalkolik yagli karaciger hastaligi gelisim riskini arttirmaktadir. Inflamatuvar bagirsak hastalarinda sistemik iltihaplanma ve bagirsak mikrobiyomunun degismesi nonalkolik yagli karaciger hastaligi gelisiminde potansiyel nedensel faktörler olarak belirtilmistir, ancak patofizyolojiyi aydinlatmak için daha fazla çalismaya ihtiyaç duyulacaktir.
Abstract
Background and Aims: Nonalcoholic fatty liver disease is common among patients with inflammatory bowel disease. We aimed to evaluate and compare the prevalence of nonalcoholic fatty liver disease in inflammatory bowel disease cases and matched controls, and to define the features of nonalcoholic fatty liver disease associated with inflammatory bowel disease. Materials and Methods: The medical recordsof 225 patients with inflammatory bowel disease who underwent ultrasonography examination for abdominal pain in our gastroenterology clinic were analyzed retrospectively. The records of these cases were compared with those of 70 controls without inflammatory bowel disease, matched for age, body mass index, and the presence of Diabetes Mellitus. Abdominal ultrasonography findings were analyzed for the presence or absence of hepatosteatosis. Results: The rate of nonalcoholic fatty liver disease in the study population was 38.3%. Nonalcoholic fatty liver disease was observed at a significantly higher rate in the inflammatory bowel disease patient group than in the control group (43.3% versus 25%; p = 0.004). Nonalcoholic fatty liver disease was observed at a significantly higher rate in the ulcerative colitis subgroup than in the control group (43.9% versus 25%, p = 0.007). A significantly higher percentage of nonalcoholic fatty liver disease was observed in the Crohn’s disease subgroup than in the control group (42.4% versus 25%, p = 0.015). The presence of inflammatory bowel disease, Diabetes Mellitus, and body mass index >25 were found to increase the risk independently of developing nonalcoholic fatty liver disease. Conclusion: The presence of inflammatory bowel disease increases the risk of developing nonalcoholic fatty liver disease. The current results suggest systemic inflammation and alteration of the gut microbiome in inflammatory bowel disease as causal factors in the development of nonalcoholic fatty liver disease, but further studies are required to elucidate the pathophysiology involved.
